Clinical trial
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)
NCT00133003 is registered in ClinicalTrials.gov with Deutsches Herzzentrum Muenchen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)
- Lead sponsor
- Deutsches Herzzentrum Muenchen
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 31, 2003
- Completion date
- January 31, 2006
- Enrollment
- 2,022 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.